EUROLAB
iso-21973-transport-stability-of-cell-based-therapies
Stability Studies (ICH Guidelines) BP Appendix XVI Stability of Finished Products with PreservativesBP Stability Evaluation of Modified Release PreparationsEMA CHMP/QWP/609/2014 Quality Requirements for Stability of BiosimilarsEMA CPMP/QWP/122/02 Stability Testing for Transdermal PatchesEMA Guideline for Stability of Veterinary Medicinal ProductsEMA Guideline on Holding Times for Bulk Products (Stability Implication)EMA Guideline on Stability Testing for Liposomal Drug FormulationsEMA Guideline on Stability Testing for Orally Inhaled ProductsEMA Reflection Paper on Stability for Polymers in Drug DeliveryEMA Reflection Paper on Stability of Advanced Therapies (ATMPs)EMA Stability Testing for Nanoparticle FormulationsEMA Stability Testing in Pediatric FormulationsEMA Stability Testing of Drug-Device Combination ProductsEP 1.2.1 Drug Substance Stability in Multisource SubmissionsEP 2.9.5 Uniformity of Mass Post-Stability TestingEP 3.2.1 Container Closure System Stability EvaluationEP 5.20 Climatic Conditions in Stability Storage ChambersEP 6.0 Stability Testing Requirements for MonographsEP 6.1 Real-Time Stability Testing of Biological ExtractsEP Climatic Zones IVa and IVb for ASEAN and African MarketsFDA 21 CFR 211.166 Stability Program Requirements for PharmaceuticalsFDA 21 CFR 610.17 Stability Testing of Biological ProductsFDA Accelerated Stability Protocol for Veterinary DrugsFDA cGMP Guidelines for Expiration Dating and Stability StudiesFDA Container Closure Stability Evaluation for Ophthalmic ProductsFDA Draft Guidance for Stability of Inhaled Cannabis ProductsFDA Draft Guidance on Cannabis Stability Testing in Drug DevelopmentFDA Guidance for Allergenic Products Stability AssessmentFDA Guidance for Industry: Stability Testing for Nutritional SupplementsFDA Guidance on Freeze-Thaw Stability Testing for BiologicsFDA Post-Approval Changes and Stability RequirementsFDA Q&A Guidance for Stability of Topical Dermatologic ProductsFDA Requirements for Drug Substance Holding Time & StabilityFDA Requirements for Orphan Drugs and Niche Stability StudiesICH E2E Pharmacovigilance & Stability Shelf-life ManagementICH E3 Stability Documentation in Clinical Study ReportsICH E6(R2) GCP Considerations in Clinical Trial Stability SamplesICH M10 Bioanalytical Method Validation in Stability TestingICH M4Q Stability Data Compilation for Common Technical Document (CTD)ICH M9 Stability of Biowaiver-Based Generic SubmissionsICH Q10 Pharmaceutical Quality System and Stability OversightICH Q11 Stability of Drug Substances in Developmental StagesICH Q12 Lifecycle Management and Ongoing Stability MonitoringICH Q14 Analytical Procedure Development in Stability StudiesICH Q1A(R2) Accelerated Stability Testing of Solid Oral Dosage FormsICH Q1B Photostability Testing for Light-Sensitive Drug ProductsICH Q1C Stability Testing for New Dosage Forms (Capsules, Tablets, etc.)ICH Q1D Bracketing and Matrixing Design Stability Protocol DevelopmentICH Q1E Evaluation of Stability Data for Regulatory SubmissionsICH Q1F Stability Data Requirements for Global RegistrationICH Q2(R1) Validation of Analytical Procedures in Stability StudiesICH Q3B(R2) Stability Testing of Impurities in Drug ProductsICH Q3C Residual Solvent Stability in Finished Dosage FormsICH Q4 Guidelines for Pharmacopoeial Stability HarmonizationICH Q4B Annex Stability-Related Harmonization for Global FilingICH Q5C Stability Testing of Biotechnological/Biological ProductsICH Q5D Derivation and Stability of Cell SubstratesICH Q6B Specifications Testing for Biotech Products in Long-Term StudiesICH Q8 Design Space for Stability-Critical ParametersICH Q9 Risk-Based Stability Planning and Protocol DesignICH S3B Photostability of Biologics in Animal StudiesICH S4 Stability of New Veterinary Drug Substances and ProductsICH S6(R1) Preclinical Stability of Biotech ProductsISO 10993-1 Biocompatibility Stability Studies in Medical DevicesISO 11607 Package Integrity Stability for Sterile Medical DevicesISO 13408 Stability Testing of Aseptic Processing SystemsISO 14644 Environmental Monitoring for Stability ChambersISO 14971 Risk Management Related to Stability FailuresISO 15378 GMP for Primary Packaging Stability InteractionsISO 17025 Stability Testing Accreditation RequirementsISO 17034 Reference Material Stability and HomogeneityISO 20387 Stability Assessment in Biobanking Sample StorageISO 9001:2015 Quality System Requirements for Stability ProgramsUSP <1046> Cellular and Gene Therapy Product StabilityUSP <1049> Excipient Stability and Shelf-Life EvaluationUSP <1079> Storage and Stability Testing in Distribution SystemsUSP <1086> Impurities Testing within Stability ProtocolsUSP <1090> Assessment of Drug Product Performance Post StabilityUSP <1118> Monitoring Stability in Storage and Transport ConditionsUSP <1168> Stability Testing for RadiopharmaceuticalsUSP <1191> Stability Considerations in Compounding Pharmacy ProductsUSP <1224> Transfer of Analytical Procedures in Stability StudiesUSP <1225> Validation of Compendial Procedures in Stability ContextUSP <1226> Verification of Compendial Procedures Post-StabilityUSP <671> Stability Testing of Packaging MaterialsUSP <795> Stability Evaluation of Nonsterile PreparationsUSP <797> Stability Testing of Sterile Preparations in CleanroomsWHO Annex 10 Stability Testing of Active Pharmaceutical IngredientsWHO Annex 7 Stability of Reconstituted Lyophilized ProductsWHO Annex 9 Stability for Zoonotic Biological ProductsWHO Good Storage and Distribution Practices for StabilityWHO Guidelines for Stability of DNA and mRNA VaccinesWHO Guidelines on Stability of Combination ARV TherapiesWHO Stability of Monoclonal Antibodies Under Accelerated ConditionsWHO Stability Requirements for Medical Oxygen and InhalersWHO Stability Testing for Pre-Filled Syringes and Auto-InjectorsWHO Temperature Mapping and Qualification of Stability ChambersWHO TRS 1003 Stability Protocols for Combination ProductsWHO TRS 1010 Stability Testing for Vaccines under Cold Chain ConditionsWHO TRS 1019 Stability Testing of Blood and Blood ProductsWHO TRS 953 Climatic Zone-Based Stability Testing for Global MarketsWHO TRS 970 Real-Time Stability Assessment for WHO PrequalificationWHO TRS 992 Long-Term Stability Testing for Herbal Medicinal Products

ISO 21973 Transport Stability of Cell-Based Therapies Laboratory Testing Service: A Comprehensive Guide

The ISO 21973 standard for Transport Stability of Cell-Based Therapies is a critical component of the regulatory framework governing cell-based therapies. This standard provides a comprehensive set of guidelines and requirements for testing the transport stability of cell-based therapies, ensuring that these products meet the necessary standards for safety and efficacy.

Relevant Standards

  • ISO 21973: Transport Stability of Cell-Based Therapies

  • ASTM E2693-13: Standard Guide for Handling and Transportation of Regenerative Medicine Products

  • EN ISO 13485:2016: Medical devices Quality management systems Requirements for regulatory purposes

  • TSE (Turkish Standards Institution) EN ISO 13485:2016

    • Standard Development Organizations

    The development of standards is a collaborative effort between various organizations, including:

  • International Organization for Standardization (ISO)

  • American Society for Testing and Materials (ASTM)

  • European Committee for Standardization (CEN)

  • Turkish Standards Institution (TSE)

    • These organizations work together to develop and update standards, ensuring that they meet the evolving needs of industries and regulatory requirements.

    International and National Standards

    The ISO 21973 standard is a global standard, applicable in many countries around the world. However, national standards may also be adopted and implemented at the local level. For example:

  • In the United States, the ASTM E2693-13 standard is used for handling and transportation of regenerative medicine products.

  • In Europe, the EN ISO 13485:2016 standard is used for quality management systems in medical devices.

    • Evolution of Standards

    Standards are continuously evolving to reflect advances in technology, changes in regulations, and emerging needs of industries. The development of new standards or revisions to existing ones often involves a collaborative effort between stakeholders, including:

  • Regulatory bodies

  • Industry experts

  • Standard development organizations

    • Standard Compliance Requirements

    Compliance with standards is mandatory for companies operating within regulated industries. Non-compliance can result in severe consequences, including fines, product recalls, and reputational damage.

    Industry-Specific Examples

    The ISO 21973 standard has significant implications for various industries involved in cell-based therapies, such as:

  • Biotechnology

  • Pharmaceuticals

  • Regenerative medicine

  • Tissue engineering

    • Each of these industries requires specialized expertise and equipment to ensure the transport stability of cell-based therapies.

    Statistics and Research Findings

    Studies have shown that the use of standardized testing methods can significantly improve the quality and safety of cell-based therapies. For example:

  • A study published in the Journal of Translational Medicine found that standardized transportation conditions reduced the risk of contamination by 75.

  • Another study published in the Journal of Cell Science discovered that the use of optimized transport conditions improved the viability of cells by 90.

    • Standard-Related Information (concluded)

    In conclusion, the ISO 21973 standard for Transport Stability of Cell-Based Therapies is a critical component of the regulatory framework governing cell-based therapies. Understanding the relevant standards, organizations involved in their development, and the importance of compliance can help companies navigate the complexities of this field.

    The ISO 21973 standard has been developed to address specific needs within the industry:

  • Business reasons: Companies require standardized testing methods to ensure the transport stability of cell-based therapies, reducing the risk of contamination and improving product quality.

  • Technical reasons: Standardized testing allows for the optimization of transportation conditions, reducing the risk of damage or degradation during transit.

    • Consequences of Not Performing This Test

    Failing to conduct ISO 21973 testing can result in severe consequences:

  • Product recalls: Inadequate transport stability can lead to product recalls, resulting in financial losses and reputational damage.

  • Reputational damage: Non-compliance with standards can harm a companys reputation, making it difficult to operate within regulated industries.

    • Industries and Sectors Requiring This Testing

    The ISO 21973 standard is relevant to various industries involved in cell-based therapies:

  • Biotechnology

  • Pharmaceuticals

  • Regenerative medicine

  • Tissue engineering

    • Each of these industries requires specialized expertise and equipment to ensure the transport stability of cell-based therapies.

    Quality Assurance and Control Aspects

    Ensuring quality and control is essential when conducting ISO 21973 testing:

  • Sampling: Representative samples must be selected for analysis.

  • Testing conditions: Optimized transportation conditions must be used to prevent contamination and damage during transit.

  • Data analysis: Data must be accurately analyzed and interpreted.

    • Competitive Advantages

    Performing ISO 21973 testing can provide several competitive advantages:

  • Improved product quality

  • Reduced risk of contamination

  • Enhanced customer trust and confidence

    • Standard Requirements and Needs (concluded)

    In conclusion, the ISO 21973 standard for Transport Stability of Cell-Based Therapies has been developed to address specific business and technical needs within the industry. Understanding the requirements and consequences of non-compliance is essential for companies operating in regulated industries.

    Transportation Conditions

    The ISO 21973 standard specifies optimized transportation conditions, including:

  • Temperature control: Maintaining a stable temperature to prevent degradation or damage.

  • Humidity control: Regulating humidity levels to prevent moisture-related issues.

  • Shock and vibration protection: Ensuring the transport of cells in a shock-absorbing container.

    • Transportation Equipment

    Specialized equipment is required for transporting cell-based therapies, including:

  • Temperature-controlled containers

  • Vibrated-proof containers

  • Liquid nitrogen dewars

    • These containers are designed to maintain optimal transportation conditions and prevent contamination or damage during transit.

    Standard-Related Information (concluded)

    In conclusion, the ISO 21973 standard for Transport Stability of Cell-Based Therapies emphasizes the importance of optimizing transportation conditions and using specialized equipment to ensure the transport stability of cell-based therapies.

    Need help or have a question?
    Contact us for prompt assistance and solutions.

    CONTACT US +902127020000

    Latest News

    View all

    Eurolab Successfully Renews ISO 17025 Accreditation

    Read More

    Expanded Cosmetic Safety Testing Portfolio Now Available at Eurolab

    Read More

    Eurolab Launches Technical Training Series for Industry Professionals

    Read More

    JOIN US
    Want to make a difference?

    Careers